

## Innovation Ecosystem Programme

# Learning Collaborative – Learning by doing Workstream 1

Outputs from virtual workshop – 11 December 2023

Innovation, Research, Life Sciences and Strategy (IRLSS) team (NHS England), with Health Innovation Wessex, Health Innovation South West, and Health Innovation West of England.





# Context



Health  
Innovation  
Wessex



Health  
Innovation  
South West



Health Innovation  
West of England

- **Monday 11 December 2023** was the kick-off meeting of the Innovation Ecosystem Review Programme, Workstream 1: Learning by doing. 76 delegates were welcomed by NHS England's Innovation, Research, Life Sciences and Strategy (IRLSS) team, along with Health Innovation Wessex, Health Innovation South West, and Health Innovation West of England.
- The aim of the first Learning by doing workstream and rapid insight (RI) event was to **generate insights** from the health innovation ecosystem including NHS, academia, industry, and patients/public. The session was based on a series of hypotheses derived from learning from national innovation and adoption programmes.
- The kick-off meeting was the first step in this journey, by **collaborating and learning** from transformation initiatives across the innovation pathway. Please note, for the mind map analysis, we have used the first iteration of the hypotheses, which were then subsequently refined on the back of feedback to simplify the language.
- This in turn will enable the **refinement** of the NHS Research and Innovation Blueprint (an output of Workstream 3) of how to improve research mobilisation and the spread and adoption of innovation. This output should be read in tandem to the Summary Rapid Insight Analysis – Innovation Ecosystem Programme report [11 December 2023].





# Workstream 1 (WS1): Learning by doing - Overview

The goal of WS1 is to **generate insights** from the **health innovation ecosystem** including **NHS, academia, industry, and patients/public**, to **collaborate and learn** from **pathway transformation initiatives** across the **innovation pathway**.

The specific focus will be on addressing challenges related to **Life Sciences Vision (LSV)** mission areas, which include early detection of cancer, mental health, dementia, obesity, and cardiovascular disease (CVD).

We will take the following approach:

## Learning from previous work

Taking valuable insights from past national innovation spread and adoption programmes for the purpose of developing actionable hypotheses which identify pivotal enablers for the adoption and spread of innovative practices.



## Learning Collaborative & locality partnerships

Recognising the importance of system-led pathway transformation, we propose partnering with select localities on their ongoing transformation initiatives to capture learning and identify areas for system improvement.





# Rapid insight methodology

**The aim of rapid insight was to capture and enable rapid analyses from localities to explore and test the innovation ecosystem hypotheses derived from previous national spread and adoption programmes.**

The methodology is based on the Health Innovation Wessex rapid insight approach ([Chandler et al, 2023](#)).

Our approach has helped identify some of the most important insights that were made during the session.

This is an optimal approach as it

- is underpinned by expertise in implementation science
- is a tried and tested model that yields excellent outputs
- builds on the wealth of experience of using the diagnostic tool
- can be delivered at pace.

Through a **rapid cycle of data collection, analysis, and feedback**, our outputs are presented in a 'rapid' style – **quick and easy to digest format for immediate assimilation.**





# Rapid insight questions

## Event objective

Building on the locality project submissions from systems during September/October 2023, there was an opportunity to take part in a fast-paced intelligence gathering, rapid insight session to obtain views and opinions. These findings have contributed to the testing and exploration of nine draft innovation adoption hypotheses. **Appendix A** describes the nine hypotheses explored. Attendees were asked to respond as follows:

**Does this hypothesis resonate or not? Please explain why.**

Respondents were asked to tag their answer to enable locality/health innovation network identification:

#ICS

Example below only:

#NHSSomerset [example]


From this analysis we identified overarching themes which have been captured in the summary analysis from the initial meeting.



# High level summary statistics



**76** attendees at event  
[one MS Form follow up]  
with **excellent retention rate** until the end of the session



**46%** locality attendees  
**12** health innovation networks represented  
**22** other organisations represented (including 4 innovators)



**356** responses received for analysis\*

\*17 responses excluded as they were not relevant to the innovation ecosystem hypothesis





# Innovation Ecosystem Review stakeholders

We welcomed colleagues from across localities and health innovation networks from the following job roles [a representation]:

Associate Director  
CCIO  
CEO  
CIO  
Clinical Director for Research  
Co-CEO  
Commercial Director  
Commissioning Manager  
COO  
Deputy CEO  
Digital Lead  
Director of Clinical Innovation Adoption  
Director of Communications  
Director of Discovery  
Director of Implementation  
Director of Improvement and Insight  
Director of Innovation  
Director of Innovation Adoption

Director of Programmes  
Director of Strategy  
Head of Business Development  
Head of Business Planning  
Head of Commercial Innovation and Growth  
Head of Communications  
Head of Evaluation and Transformation  
Managing Director  
National Director  
Programme Delivery Director  
Programme Director  
Programme Director Industry and Commercial Partnerships  
Programme Manager Clinical Innovation and Adoptions  
Programme Manager for Cancer Innovation  
Senior Business Developer  
Senior Implementation and Evaluation Manager  
Senior Improvement Lead  
Senior Programme Manager





# Rapid insight analysis







# Guide to interpreting the mind maps

[n=42]

Where 'n' has been presented on the mind maps, this includes the number of responses which have been further sub themed. Due to the richness of data, the comments analysed often applied to more than one identified theme; therefore, the total number of comments will not equate to the number of comments relevant to each theme.



Key theme description

Key theme connection

Further sub theme [identification of further rich data]






## Hypothesis 1:

Taking a whole **pathway** approach, considering clinical, patient, staff and system benefits, to embed specific innovations is more likely to lead to sustained adoption and spread.



# Pathways are fundamental because they:






## Hypothesis 2:

Spread and adoption of innovation is more difficult without a clear, relevant national strategy and **policy levers that align with local needs**, particularly when it comes to implementation. However, national implementation policy should not be too prescriptive, and aligning national ambition with regional and local needs will accelerate the adoption of proven innovations.





# Aligned levers need to provide:





This resonates, but we need to ensure that the needs of our diverse communities are reflected and heard within this. This is where local work, designed in partnership with local communities, can lead to innovation designed for a specific community, where it is possible to share for smaller communities with similar needs across the country (where a single national programme would not be appropriate). HEAL-D is an example.

Representative from a health innovation network






## Hypothesis 3:

The perceived **utility** of the innovation, including relative advantage, alignment with existing workflows, simplicity of use and cultural fit, is crucial for success. This is understood through relational work with the adopters of the innovation, understanding of complex systems and evaluation of real-world impact, supported by continuous learning.



# Utility is important and must be considered alongside the following aspects:







## Hypothesis 4:

Effective clinical and practitioner **leadership** at both national and local level is essential to enable successful spread and adoption of innovation. Local clinical leadership is particularly important to mobilise resources and engage stakeholders.





“

Given the way the system works, this is the only way to do it. Part of the great thing about having ICBs is that it is possible to join funding and coordination up across the system, particularly between primary and secondary care and the broader interaction with the public.

”

Innovator





“

**Clinical champions who can tell a persuasive story with facts, figures, and quotes will be pivotal [...] Reflective practice is vital in all aspects, but how do we achieve this meaningfully on the ground?**


”

Representative from a health innovation network





# Leadership is important, but also consider:






## Hypothesis 5:

Timely national and local quantitative uptake **data**, and qualitative information on enablers and barriers to adoptions, is necessary to increase contextual understanding and will build and drive behaviour change in a culture of learning and reflective practice.





# The data hypothesis resonates but it needs to be...






## Hypothesis 6:

Participative **decision making** across the adopting team, led by managers and leaders through the development of a robust business case that can demonstrate both clinical benefits and resource impact (ideally cost savings), is key to ensure sustained adoption.



# Participative decision making is integral but:








## Hypothesis 7:

A robust **evidence base** demonstrating both clinical efficacy and return on investment and value, and health and social care workforce impact will be a key driver in supporting the spread and adoption of specific innovations.





# An evidence base is key, but consider:





“

**If you turn the hypothesis around and ask, "If there is no evidence, would this facilitate adoption and spread?" then the answer would be a clear 'no'.**

”

Representative from a health innovation network






## Hypothesis 8:

The informal system, defined as people in the **workforce** who often work unseen with their network to drive continuous improvement, are vital for successful innovation adoption. Growing our informal system by enhancing the capability and capacity of the whole health and care workforce with skills in pathway transformation and adoption of innovation will enable more effective spread and adoption of innovation.





# Within the innovation ecosystem, considerations for the workforce include:





## Hypothesis 9:

Spread and adoption of innovation at pace and scale requires a continuous, iterative **process** that learns from local adaptation, fidelity requirements and implementation, and the use of different national and local system levers in diverse systems.






# Understanding the process across the whole innovation ecosystem pathway is imperative.

The elements that need to be considered alongside the hypotheses are:

Short-term complexity




Adaptability to place



Relationships grounded in clinical pathways



Demonstrating impact at scale



Sharing learning



Moving to business as usual (BAU)



[n=29]





Yes, innovation adoption is not a straight line but more like spiral loop where, as we work on having the innovation adopted, the more we learn and the more we understand the system within which we operate. That leads us back to revisit our early assumptions, clarify further our problem statements, and see how the system has responded to the early stimuli so we can adapt our approach.

Representative from a health innovation network







“

**[...] sometimes great innovations get lost in the complexity of the business case arena.**

”

NHS organisation





# Missing hypotheses and pre-requisites for an innovation ecosystem





# Pre-requisites for an innovation ecosystem

Question 10 encouraged the group to reflect on any hypotheses that were missing from the original nine hypotheses. On reviewing, these areas could be considered as pre-requisites for an innovation ecosystem and responses echoed feedback across other hypotheses. These include:



Patient [and  
community]  
voice



Financial  
stability



Support from  
transformation  
teams



Addressing cross  
cutting themes  
including health  
inequalities



Adaptability  
to place



Sharing best  
practice with  
decision makers



Alignment of  
multiple strategies  
to enable  
scalability



Moving from  
policy/management  
approach to business as usual  
**(Responsible, Accountable,  
Consulted, Informed)**



Health Innovation Wessex  
Innovation Centre  
Southampton Science Park  
2 Venture Road  
Chilworth  
Southampton  
SO16 7NP

E: [enquiries@hiwessex.net](mailto:enquiries@hiwessex.net)  
@HIWessex  
T: 023 8202 0840

[healthinnovationwessex.org.uk](http://healthinnovationwessex.org.uk)

Part of the  
**Health  
Innovation**  
Network